搜尋
InMed Pharmaceuticals Inc
INM添加自選
1.460USD
-0.040-2.67%
收盤 07-31 16:00（美東）報價延遲15分鐘
4.09M總市值
虧損本益比TTM
關於 InMed Pharmaceuticals Inc 公司
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
InMed Pharmaceuticals Inc簡介
公司代碼INM
公司名稱InMed Pharmaceuticals Inc
上市日期Jun 21, 2001
CEOAdams (Eric A)
員工數量- -
證券類型Ordinary Share
年結日Jun 21
公司地址1445-885 West Georgia St.
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編V6C 3E8
電話16046697207
網址https://www.inmedpharma.com/
公司代碼INM
上市日期Jun 21, 2001
CEOAdams (Eric A)
InMed Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
常見問題
InMed Pharmaceuticals Inc的前五大股東是誰？
InMed Pharmaceuticals Inc的前五大股東如下：Mr. Andrew Harold Hull
有多少機構持有InMed Pharmaceuticals Inc(INM)的股份？
截至2026Q1，共有31家機構持有InMed Pharmaceuticals Inc的股份，合計持有的股份價值約為320.11K，占公司總股份的9.66% 。與2025Q4相比，機構持股有所增加，增幅為-43643.00。